Companies and People News for September 2013

Companies and People News Archive

Ablynx and Merck Serono Further Strengthen Their Collaboration on Co-Discovery and Co-Development Of Nanobodies Ablynx and Merck Serono Further Strengthen Their Collaboration on Co-Discovery and Co-Development Of Nanobodies

Creation of dedicated discovery unit at AblynxDiscovery and development of Nanobodies® against multiple targets in Merck Serono’s core therapeutic areas

Cell Medica opens commercial manufacturing facility in Germany Cell Medica opens commercial manufacturing facility in Germany

Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces that portfolio company Cell Medica, a leading T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany.

As Alzheimer’s Burden Rises, Global Action Needed to Accelerate Research on New Treatments and Prevention As Alzheimer’s Burden Rises, Global Action Needed to Accelerate Research on New Treatments and Prevention

New York Academy of Sciences, in partnership with The Global CEO Initiative on Alzheimer’s Disease and the National Institute on Aging/NIH, to Launch “Path to 2025” Biennial Summit to Drive Progress in Alzheimer’s R&D over Next Decade

Spin-out company Molecular Profiles purchased by US-based Columbia Laboratories Spin-out company Molecular Profiles purchased by US-based Columbia Laboratories

Molecular Profiles, one of The University of Nottingham’s longest established spin-out businesses, has been purchased by Columbia Laboratories, Inc. (Nasdaq: CBRX) of Boston, for approximately $25m (£16m).Molecular Profiles was established in 1997 by an academic group at The University of Nottingham’s School of Pharmacy, who identified an opportunity to deliver sophisticated analytical and development solutions to meet the growing needs of the pharmaceutical industry.

ClinTec International announced as SCRIP Awards 2013 finalist in the category of ‘Best CRO’ in recognition of continued corporate success ClinTec International announced as SCRIP Awards 2013 finalist in the category of ‘Best CRO’ in recognition of continued corporate success

ClinTec International, the global Clinical Research Organisation has been named as a finalist for the accolade of ‘Best CRO’ at the SCRIP Awards 2013, to be held in London’s Lancaster Hotel on November 21st, 2013. Being on the final shortlist for this accolade, at what is one of the biggest ceremonies in the pharmaceutical industry, marks a further landmark in what has been a successful year for the company.

Cancer Research Technology andTeva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs Cancer Research Technology andTeva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs

Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

MED-EL Founder and CEO Dr. Ingeborg Hochmair to Receive Prestigious Lasker Award for Development of the Modern Cochlear Implant MED-EL Founder and CEO Dr. Ingeborg Hochmair to Receive Prestigious Lasker Award for Development of the Modern Cochlear Implant

Worldwide hearing implant leader MED-EL Medical Electronics today announced that its Founder and CEO Ingeborg Hochmair, PhD, has been selected to receive this year's prestigious Lasker-DeBakey Clinical Medical Research Award for the development of the modern cochlear implant, a device that restores hearing to individuals with severe-to-profound deafness through electrical stimulation of the auditory nerve. She will share the award with Graeme M. Clark (Emeritus, Univ. of Melbourne, Australia) and Blake S. Wilson (Duke University, NC, USA). This highly-respected scientific award honors scientists whose contributions have improved the clinical treatment of patients. The award ceremony will take place in New York City on Friday, September 20, 2013

Zealand announces peptide drug research and development collaboration agreement with Lilly Zealand announces peptide drug research and development collaboration agreement with Lilly

Zealand Pharma has announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly and Company (“Lilly”).

Wellcome Trust and KU Leuven announce collaboration with Janssen for development of dengue antiviral drugs Wellcome Trust and KU Leuven announce collaboration with Janssen for development of dengue antiviral drugs

Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.